Cagnin Annachiara, Kassiou Michael, Meikle Steve R, Banati Richard B
Department of Neuroscience, University of Padova, Via Giustiniani 5, 35128, Padova, Italy.
Neurotherapeutics. 2007 Jul;4(3):443-52. doi: 10.1016/j.nurt.2007.04.006.
In the diseased brain, upon activation microglia express binding sites for synthetic ligands designed to recognize the 18-kDa translocator protein TP-18, which is part of the so-called peripheral benzodiazepine receptor complex. PK11195 [1-(2-chlorophenyl)-N-methyl-N-(1-methylpropyl)-3-isoquinoline carboxamide], the prototype synthetic ligand, has been widely used for the functional characterization of TP-18. Its cellular source in activated microglia has been established using high-resolution, single-cell autoradiography with the R-enantiomer 3H-PK11195. Radiolabeled 11C-PK11195 has been used to image active brain disease with positron emission tomography. Consistent with experimental and postmortem observations of a characteristically distributed pattern of microglia activation in areas of focal pathology, as well as in anterograde and retrograde projection areas, the in vivo regional 11C-PK11195 signal is found in active focal lesions and over time also along the affected neural tracts and their respective cortical and subcortical projection areas. Thus, a profile of active disease emerges that matches some of the typical distribution patterns known from structural neuroimaging techniques, but additionally shows involvement of brain regions linked through neural pathways. In the context of cell-based in vivo neuropathology, the image data are thus best interpreted in the context of the emerging cellular understanding of brain disease or damage, rather than the definitions of clinical diagnosis. One important observation, borne out by experiment, is the long latency with which activated microglia or increased PK11195 retention appear to gradually emerge and remain in distal areas secondarily affected by disease, supporting speculations that the presence of activated microglia is an important corollary of brain plasticity.
在患病大脑中,小胶质细胞激活后会表达合成配体的结合位点,这些配体旨在识别18 kDa转位蛋白TP - 18,它是所谓外周苯二氮䓬受体复合物的一部分。原型合成配体PK11195 [1 - (2 - 氯苯基)-N - 甲基 - N - (1 - 甲基丙基)-3 - 异喹啉甲酰胺]已被广泛用于TP - 18的功能表征。利用高分辨率单细胞放射自显影技术结合R - 对映体3H-PK11195,已确定其在激活的小胶质细胞中的细胞来源。放射性标记的11C-PK11195已被用于正电子发射断层扫描成像活跃的脑部疾病。与局灶性病变区域以及顺行和逆行投射区域中小胶质细胞激活特征性分布模式的实验和尸检观察结果一致,在体内,11C-PK11195信号出现在活跃的局灶性病变中,并且随着时间的推移,也出现在受影响的神经束及其各自的皮质和皮质下投射区域。因此,出现了一种活跃疾病的特征,它与结构神经成像技术已知的一些典型分布模式相匹配,但此外还显示出通过神经通路相连的脑区也受到影响。在基于细胞的体内神经病理学背景下,因此最好在对脑部疾病或损伤的细胞理解不断涌现的背景下解释图像数据,而不是临床诊断的定义。一个重要的实验观察结果是,激活的小胶质细胞或PK11195保留增加似乎在疾病继发影响的远端区域逐渐出现并持续存在的潜伏期很长,这支持了关于激活的小胶质细胞的存在是脑可塑性的一个重要推论的推测。